Beech, nuts is right. It is also very common that the control group members leave trials to try other treatments/ trials and therefore unlikely to be why the cause of any delay of the interim 2b data.
When an open trial is proving to have strong initial results within the treatment group it is unethical not to give late stage patients in the control group the same treatment, which is what herro has mentioned above.
- Forums
- ASX - By Stock
- IMM
- food for thought
food for thought, page-10
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M |
Open | High | Low | Value | Volume |
33.5¢ | 34.0¢ | 33.0¢ | $1.220M | 3.642M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 57289 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 52306 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 57289 | 0.330 |
5 | 29051 | 0.325 |
7 | 113477 | 0.320 |
1 | 55000 | 0.315 |
3 | 48550 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 52306 | 3 |
0.345 | 73155 | 7 |
0.350 | 100659 | 8 |
0.355 | 147500 | 3 |
0.360 | 123645 | 5 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |